<p>Sight Sciences, Inc.（纳斯达克代码：SGHT - 获取免费报告）的股票被九家评级机构一致推荐为 “持有”，Marketbeat Ratings 报告称。一位分析师给予该股票 “卖出” 评级，三位分析师给予 “持有” 评级，五位分析师给予 “买入” 评级。在过去一年中，发布报告的分析师对该股票的平均十二个月目标价为 8.3125 美元。</p>
<p>获取 <strong>Sight Sciences</strong> 的提醒：</p>
<p>SGHT 已成为多份分析师报告的主题。Stifel Nicolaus 在 3 月 2 日的报告中将 Sight Sciences 的股票目标价从 6.00 美元上调至 8.00 美元，并给予该股票 “买入” 评级。Cantor Fitzgerald 在 3 月 2 日的报告中设定了 8.00 美元的目标价。William Blair 在 3 月 5 日的研究报告中重申了对 Sight Sciences 的 “跑赢大盘” 评级。瑞士银行集团在 3 月 6 日的报告中将 Sight Sciences 的目标价从 12.00 美元下调至 11.00 美元，并对该股票给予 “买入” 评级。最后，花旗集团在 3 月 6 日的研究报告中将 Sight Sciences 的目标价从 9.10 美元下调至 6.50 美元，并对该公司给予 “中性” 评级。</p>
<p><strong>查看我们对 SGHT 的最新股票分析</strong></p>
<h2>内部人士下注</h2>
<p>在其他新闻中，内部人士 Jeremy B. Hayden 于 4 月 6 日星期一出售了 13,761 股公司的股票。该股票以平均价格 3.55 美元出售，总价值为 48,851.55 美元。交易完成后，该内部人士直接持有 369,770 股公司的股票，价值为 1,312,683.50 美元。这代表其持股比例减少了 3.59%。该交易已在与 SEC 的法律文件中披露，相关信息可通过此超链接获取。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，首席技术官 David Badawi 于 4 月 2 日星期四出售了 8,168 股 Sight Sciences 股票。该股票以平均价格 3.48 美元出售，总价值为 28,424.64 美元。出售后，首席技术官持有公司 1,990,290 股股票，价值为 6,926,209.20 美元。此交易代表其持股比例减少了 0.41%。有关此销售的更多细节可在官方 SEC 披露中找到。在过去三个月中，内部人士出售了 61,273 股公司股票，价值为 221,764 美元。内部人士持有公司 30.90% 的股票。</p>
<h2>机构投资者对 Sight Sciences 的看法</h2>
<p>一些对冲基金最近对其在该公司的持仓进行了调整。Americana Partners LLC 在第三季度将其在 Sight Sciences 的持仓增加了 42.4%。Americana Partners LLC 现在拥有 1,229,819 股公司的股票，价值为 4,231,000 美元，此前在该期间又购买了 365,901 股。制造商人寿保险公司在第四季度购买了价值约 96,000 美元的 Sight Sciences 新股份。XTX Topco Ltd 在第二季度购买了价值约 67,000 美元的 Sight Sciences 新股份。法国巴黎银行金融市场在第三季度将其在 Sight Sciences 的持仓增加了 99.8%。法国巴黎银行金融市场现在拥有 7,579 股公司的股票，价值为 26,000 美元，此前在上个季度又收购了 3,785 股。最后，Dimensional Fund Advisors LP 在第一季度将其在 Sight Sciences 的持仓增加了 13.4%。Dimensional Fund Advisors LP 现在拥有 341,681 股公司的股票，价值为 1,288,000 美元，此前在该期间又收购了 40,346 股。55.51% 的股票目前由机构投资者持有。</p>
<h2>Sight Sciences 股票上涨 6.1%</h2>
<p>SGHT 股票在周五开盘价为 5.20 美元。Sight Sciences 的十二个月低点为 3.11 美元，十二个月高点为 9.24 美元。该公司的速动比率为 5.48，流动比率为 5.86，债务与股本比率为 0.68。该股票的 50 日移动平均线为 4.06 美元，200 日移动平均线为 5.85 美元。该公司的市值为 2.8293 亿美元，市盈率为-7.32，贝塔值为 2.38。</p>
<p>Sight Sciences（纳斯达克代码：SGHT - 获取免费报告）最后一次公布季度财报是在 5 月 6 日星期三。该公司报告每股收益（EPS）为-0.24 美元，低于市场共识预期的-0.19 美元，差距为 0.05 美元。该公司季度收入为 1970 万美元，而市场共识预期为 1847 万美元。Sight Sciences 的股本回报率为-52.34%，净利润率为-46.83%。卖方分析师预计 Sight Sciences 在当前财政年度将发布-0.6 的每股收益。</p>
<h2>关于 Sight Sciences</h2>
<p>（获取免费报告）</p>
<p>Sight Sciences, Inc 是一家医疗设备公司，专注于开发和商业化微创治疗慢性眼病的方案。该公司的旗舰产品包括 OMNI® 外科系统，旨在解决眼睛自然排水通道中的多个阻力点，以降低青光眼患者的眼内压，以及 TearCare® 系统，这是一种可穿戴设备，通过针对性的热脉冲治疗来治疗睑板腺功能障碍和干眼症。</p>
<p>自 2012 年成立并在纳斯达克上市以来，Sight Sciences 一直在追求将研究驱动的产品开发与直接销售模式相结合的战略。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票比 Sight Sciences 更好</li>
<li>YETI 在财报超预期和上调前景后反弹</li>
<li>三家领先的量子公司在第一季度财报后的表现对比</li>
<li>思科的垂直反弹可能仍处于早期阶段</li>
<li>亚马逊与阿里巴巴：现在显然更具价值的选择</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Sight Sciences 吗？</h2>
<p>在考虑 Sight Sciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Sight Sciences 并不在名单上。</p>
<p>虽然 Sight Sciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

SGHT

罗素 2000 成长股指数 ETF - iShares

美国小盘股多因素 MSCI ETF - iShares

标普健康医疗设备 ETF - SPDR

美国医药设备 ETF - iShares

<p>Sight Sciences, Inc.（纳斯达克代码：SGHT）获得了九位分析师的共识推荐为 “持有”。平均目标价格为 8.31 美元，其中包括一项卖出评级、三项持有评级和五项买入评级。最近的内部交易包括首席财务官 Jeremy B. Hayden 出售了 13,761 股，首席技术官 David Badawi 出售了 8,168 股。该股票目前的价值为 5.20 美元，上涨 6.1%，市值为 2.8293 亿美元。公司报告的季度每股收益为（0.24 美元），未达到预期</p>

<p>Shares of Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) have been assigned a consensus recommendation of &#34;Hold&#34; from the nine ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $8.3125.</p>
<div class="lb-trans"><p>Sight Sciences, Inc.（纳斯达克代码：SGHT - 获取免费报告）的股票被九家评级机构一致推荐为 “持有”，Marketbeat Ratings 报告称。一位分析师给予该股票 “卖出” 评级，三位分析师给予 “持有” 评级，五位分析师给予 “买入” 评级。在过去一年中，发布报告的分析师对该股票的平均十二个月目标价为 8.3125 美元。</p>
</div><p>Get <strong>Sight Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sight Sciences</strong> 的提醒：</p>
</div><p>SGHT has been the topic of a number of analyst reports. Stifel Nicolaus lifted their price objective on shares of Sight Sciences from $6.00 to $8.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, March 2nd. Cantor Fitzgerald set a $8.00 target price on shares of Sight Sciences in a report on Monday, March 2nd. William Blair reissued an &#34;outperform&#34; rating on shares of Sight Sciences in a research report on Thursday, March 5th. UBS Group cut their price target on shares of Sight Sciences from $12.00 to $11.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, March 6th. Finally, Citigroup decreased their price objective on shares of Sight Sciences from $9.10 to $6.50 and set a &#34;neutral&#34; rating for the company in a research note on Friday, March 6th.</p>
<div class="lb-trans"><p>SGHT 已成为多份分析师报告的主题。Stifel Nicolaus 在 3 月 2 日的报告中将 Sight Sciences 的股票目标价从 6.00 美元上调至 8.00 美元，并给予该股票 “买入” 评级。Cantor Fitzgerald 在 3 月 2 日的报告中设定了 8.00 美元的目标价。William Blair 在 3 月 5 日的研究报告中重申了对 Sight Sciences 的 “跑赢大盘” 评级。瑞士银行集团在 3 月 6 日的报告中将 Sight Sciences 的目标价从 12.00 美元下调至 11.00 美元，并对该股票给予 “买入” 评级。最后，花旗集团在 3 月 6 日的研究报告中将 Sight Sciences 的目标价从 9.10 美元下调至 6.50 美元，并对该公司给予 “中性” 评级。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on SGHT</strong></p>
<div class="lb-trans"><p><strong>查看我们对 SGHT 的最新股票分析</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, insider Jeremy B. Hayden sold 13,761 shares of the company's stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $3.55, for a total value of $48,851.55. Following the completion of the transaction, the insider directly owned 369,770 shares of the company's stock, valued at $1,312,683.50. This represents a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CTO David Badawi sold 8,168 shares of Sight Sciences stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $3.48, for a total value of $28,424.64. Following the sale, the chief technology officer owned 1,990,290 shares in the company, valued at $6,926,209.20. This trade represents a 0.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 61,273 shares of company stock valued at $221,764. Insiders own 30.90% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Jeremy B. Hayden 于 4 月 6 日星期一出售了 13,761 股公司的股票。该股票以平均价格 3.55 美元出售，总价值为 48,851.55 美元。交易完成后，该内部人士直接持有 369,770 股公司的股票，价值为 1,312,683.50 美元。这代表其持股比例减少了 3.59%。该交易已在与 SEC 的法律文件中披露，相关信息可通过此超链接获取。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，首席技术官 David Badawi 于 4 月 2 日星期四出售了 8,168 股 Sight Sciences 股票。该股票以平均价格 3.48 美元出售，总价值为 28,424.64 美元。出售后，首席技术官持有公司 1,990,290 股股票，价值为 6,926,209.20 美元。此交易代表其持股比例减少了 0.41%。有关此销售的更多细节可在官方 SEC 披露中找到。在过去三个月中，内部人士出售了 61,273 股公司股票，价值为 221,764 美元。内部人士持有公司 30.90% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Sight Sciences</h2>
<div class="lb-trans"><h2>机构投资者对 Sight Sciences 的看法</h2>
</div><p>A number of hedge funds have recently made changes to their positions in the business. Americana Partners LLC grew its position in Sight Sciences by 42.4% during the third quarter. Americana Partners LLC now owns 1,229,819 shares of the company's stock valued at $4,231,000 after buying an additional 365,901 shares during the period. The Manufacturers Life Insurance Company bought a new stake in Sight Sciences in the fourth quarter worth about $96,000. XTX Topco Ltd purchased a new position in Sight Sciences in the second quarter valued at about $67,000. BNP Paribas Financial Markets boosted its stake in Sight Sciences by 99.8% in the third quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company's stock valued at $26,000 after acquiring an additional 3,785 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Sight Sciences by 13.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 341,681 shares of the company's stock valued at $1,288,000 after acquiring an additional 40,346 shares during the period. 55.51% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金最近对其在该公司的持仓进行了调整。Americana Partners LLC 在第三季度将其在 Sight Sciences 的持仓增加了 42.4%。Americana Partners LLC 现在拥有 1,229,819 股公司的股票，价值为 4,231,000 美元，此前在该期间又购买了 365,901 股。制造商人寿保险公司在第四季度购买了价值约 96,000 美元的 Sight Sciences 新股份。XTX Topco Ltd 在第二季度购买了价值约 67,000 美元的 Sight Sciences 新股份。法国巴黎银行金融市场在第三季度将其在 Sight Sciences 的持仓增加了 99.8%。法国巴黎银行金融市场现在拥有 7,579 股公司的股票，价值为 26,000 美元，此前在上个季度又收购了 3,785 股。最后，Dimensional Fund Advisors LP 在第一季度将其在 Sight Sciences 的持仓增加了 13.4%。Dimensional Fund Advisors LP 现在拥有 341,681 股公司的股票，价值为 1,288,000 美元，此前在该期间又收购了 40,346 股。55.51% 的股票目前由机构投资者持有。</p>
</div><h2>Sight Sciences Stock Up 6.1%</h2>
<div class="lb-trans"><h2>Sight Sciences 股票上涨 6.1%</h2>
</div><p>SGHT stock opened at $5.20 on Friday. Sight Sciences has a twelve month low of $3.11 and a twelve month high of $9.24. The company has a quick ratio of 5.48, a current ratio of 5.86 and a debt-to-equity ratio of 0.68. The stock's 50 day moving average is $4.06 and its 200-day moving average is $5.85. The firm has a market capitalization of $282.93 million, a PE ratio of -7.32 and a beta of 2.38.</p>
<div class="lb-trans"><p>SGHT 股票在周五开盘价为 5.20 美元。Sight Sciences 的十二个月低点为 3.11 美元，十二个月高点为 9.24 美元。该公司的速动比率为 5.48，流动比率为 5.86，债务与股本比率为 0.68。该股票的 50 日移动平均线为 4.06 美元，200 日移动平均线为 5.85 美元。该公司的市值为 2.8293 亿美元，市盈率为-7.32，贝塔值为 2.38。</p>
</div><p>Sight Sciences (NASDAQ:SGHT - Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.05). The company had revenue of $19.70 million for the quarter, compared to the consensus estimate of $18.47 million. Sight Sciences had a negative return on equity of 52.34% and a negative net margin of 46.83%. Sell-side analysts expect that Sight Sciences will post -0.6 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Sight Sciences（纳斯达克代码：SGHT - 获取免费报告）最后一次公布季度财报是在 5 月 6 日星期三。该公司报告每股收益（EPS）为-0.24 美元，低于市场共识预期的-0.19 美元，差距为 0.05 美元。该公司季度收入为 1970 万美元，而市场共识预期为 1847 万美元。Sight Sciences 的股本回报率为-52.34%，净利润率为-46.83%。卖方分析师预计 Sight Sciences 在当前财政年度将发布-0.6 的每股收益。</p>
</div><h2>About Sight Sciences</h2>
<div class="lb-trans"><h2>关于 Sight Sciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company's flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye's natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.</p>
<div class="lb-trans"><p>Sight Sciences, Inc 是一家医疗设备公司，专注于开发和商业化微创治疗慢性眼病的方案。该公司的旗舰产品包括 OMNI® 外科系统，旨在解决眼睛自然排水通道中的多个阻力点，以降低青光眼患者的眼内压，以及 TearCare® 系统，这是一种可穿戴设备，通过针对性的热脉冲治疗来治疗睑板腺功能障碍和干眼症。</p>
</div><p>Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.</p>
<div class="lb-trans"><p>自 2012 年成立并在纳斯达克上市以来，Sight Sciences 一直在追求将研究驱动的产品开发与直接销售模式相结合的战略。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Sight Sciences</li>
<li>YETI Rallies After Earnings Beat and Raised Outlook</li>
<li>How the 3 Leading Quantum Firms Stack Up After Q1 Earnings</li>
<li>Cisco’s Vertical Rally May Still Be in the Early Innings</li>
<li>Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Sight Sciences 更好</li>
<li>YETI 在财报超预期和上调前景后反弹</li>
<li>三家领先的量子公司在第一季度财报后的表现对比</li>
<li>思科的垂直反弹可能仍处于早期阶段</li>
<li>亚马逊与阿里巴巴：现在显然更具价值的选择</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=SGHT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Sight Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Sight Sciences 吗？</h2>
</div><p>Before you consider Sight Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Sight Sciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Sight Sciences 并不在名单上。</p>
</div><p>While Sight Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sight Sciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Sight Sciences, Inc. (NASDAQ:SGHT) 被分析师一致推荐为 “持有”